L ynch syndrome, formerly known as hereditary nonpolyposis colorectal cancer (HNPCC), is the most common inherited colorectal cancer (CRC) predisposition syndrome, accounting for 2% to 5% of all CRCs. Lynch syndrome is caused by an autosomal-dominant mutation in one of several DNA mismatch repair genes (MSH2, MLH1, MSH6, and PMS2) or the EPCAM gene. It is estimated that 1 in 660 to 2000 people in the general population carry a Lynch syndrome mutation. 1 Lynch syndrome is associated with a 20% to 80% lifetime risk of developing CRC. 2, 3 Persons with Lynch syndrome are also at higher risk for other cancers including endometrial, ovarian, stomach, renal pelvis, and pancreatic cancers. 4 Expert guidance to help identify and care for families with Lynch syndrome can vary by region and country. For instance, 3 of the recent guidelines from major groups-the European Mallorca group, the United States Multi-Society Task Force on Colorectal Cancer, and the American Gastroenterological Association-advocate the use of universal testing of all newly diagnosed CRCs with immunohistochemistry (IHC) and/or microsatellite instability testing as a Lynch syndrome case-finding strategy. [5] [6] [7] [8] In contrast, other national and regional guidelines, such as the Australian Cancer Network, recommend a traditional testing schema using selective tumor and/or germline testing only in those families meeting clinical criteria. [9] [10] [11] [12] Prospective controlled studies have found that intensive colonoscopic screening in patients with Lynch syndrome results in a 62% reduction of CRC incidence and a 65% to 70% decrease in mortality. 13, 14 Current screening recommendations for Lynch syndrome-associated gynecologic malignancies acknowledge that these measures have not been shown to improve mortality. Prophylactic hysterectomy and oophorectomy after childbearing often are discussed as a cancer-prevention option. 15 There currently is no consensus on recommendations for other Lynch syndrome-associated malignancies.
The International Mismatch Repair Consortium (IMRC) was established to conduct research on Lynch syndrome families with the purpose of informing clinical care. 16 Our study's aims were to characterize current worldwide practice patterns regarding the diagnosis and management of Lynch syndrome among IMRC members in an effort to identify knowledge gaps that can guide research and actionable areas for policy or clinical practice.
Methods

Study Design
We performed a cross-sectional questionnaire study of clinical IMRC member institutions to characterize practice patterns. The Stanford University Institutional Review Board approved the study protocol.
Target Population
The IMRC includes 143 institutions across all continents except Antarctica, with hundreds of professionals providing clinical care to and/or conducting research on more than 8000 families with Lynch syndrome and more than 20,000 known mutation carriers. 16 Of the IMRC institutions, the 128 clinical member institutions were invited to participate (Supplementary Table 1 ).
Questionnaire Development and Dissemination
We conceptualized the following 5 themes: (1) case finding, (2) work-up and genetic testing, (3) information dissemination to at-risk family members, (4) risk management, and (5) issues for the future. Questionnaire items were informed by recommendations in major clinical guidelines as well as local practice experience. 5, 6, [9] [10] [11] [12] Issues for the future centered on potential changes in practice related to rapid advances in the fundamental understanding of disease and genomic technologies (Supplementary Appendix).
A recruitment e-mail with a link to an online REDCap (Vanderbilt University, Nashville, TN) questionnaire was sent to members of clinical IMRC institutions. Members were invited to participate with their practice teams and were asked to submit only 1 response per site based on their team's routine practices-not unique personal approaches. Responses were kept de-identified by institution and respondent. Participants stated whether quantitative answers were estimates or based on rigorous data review.
Data Management and Statistical Analysis
Response data were analyzed using SAS version 9.4 (SAS Institute, Cary, NC). Descriptive statistics (means and SDs or frequency tables) were calculated using participant responses. Comments were solicited, and these comments were summarized in a qualitative manner.
Sample Size
Fifty-eight responses were submitted, and we included the 55 complete questionnaires in our analysis, representing 63 of 128 (49%) clinical IMRC institutions in 21 countries. One respondent could represent more than 1 affiliated institution (Supplementary Table 1 ).
Responding Institutions, Team Members, and Services Provided
Respondents represented all continents except Africa ( Table 1 ). The majority of respondents (84%) were from academic and major referral centers. Fewer than half of respondents reported having local institution census information readily available to answer questions, with 55% reporting use of a best estimate for their responses. All respondents reported that they offer genetic counseling by a licensed genetic counselor or genetics specialist, and more than 50% of clinical practice teams also included oncologists or gastroenterologists (Table 1) .
Referrals and Case-Finding Practices
Of new referrals for suspected Lynch syndrome, the majority were for those persons with newly diagnosed Lynch syndrome-associated cancers (44%) or family history suggestive of Lynch syndrome (29%) ( Table 2) . Providers reported a wide range in the number of annual referrals for suspected or confirmed Lynch syndrome, from <25 to >500, with the median between 101 and 250 referrals annually (Figure 1) .
Of all respondents, 30 (56%) participated in a program based on routine widespread population tumor testing (automatic reflex tumor testing) for identifying new cases of Lynch syndrome among persons with newly diagnosed Lynch syndrome-associated cancers (Figure 2) . Among respondents who reported use of automatic reflex tumor testing, 100% reported that CRCs were tested, whereas testing in endometrial (50%) and ovarian (13%) cancers was less frequent. The majority of these programs reported no upper age limit for reflex tumor testing of CRCs (Table 2) .
Work-Up and Genetic Testing
All respondents used multiple criteria to quantitate the pretest yield of genetic testing (Supplementary Table 2 ). All respondents reported that they perform some type of tumor testing when evaluating patients or families. Many practices reported using multiple overlapping modalities for tumor testing, with almost all respondents (98%) using IHC, and the majority (78%) using microsatellite instability testing as well. To distinguish sporadic mutations from potential Lynch syndrome cases, 75% of respondents reported testing for BRAF mutation, and 56% tested for MLH1 promoter methylation. Multigene panels including not only Lynch syndrome-associated genes were used by 66% of all respondents (Supplementary  Table 2 ). Only 27% of respondents reported using newer techniques, such as tumor testing for biallelic sporadic mutations in cases in which IHC was suggestive of Lynch syndrome but no pathogenic mutations were identified on germline testing (Supplementary Figure 1) .
Respondents indicated that a majority of patients seen at their practices ultimately received a recommendation for germline testing after initial risk assessment (Supplementary Table 2 ). Overall, most respondents (82%) diagnosed on average <50 new cases of Lynch syndrome through genetic testing annually, although the range for this was wide (Supplementary Table 2 ). Lynch syndrome was newly diagnosed in roughly 1 in 5 of all referred patients (Figure 1 ).
Dissemination of Information to At-Risk Family Members, and Cascade Testing
The majority of respondents used passive means to disseminate information to at-risk family members (Supplementary Table 3 ). The majority of respondents (55%) estimated that fewer than 50% of at-risk family members undergo genetic testing (Figure 3 ).
Management Practices
Almost all respondents (98%) recommended colonoscopy at regular intervals between 1 and 2 years in persons with Lynch syndrome (Table 3 ). For patients with Lynch syndrome who subsequently were diagnosed with CRC, respondents reported that decisions for surgical interventions often were made by-or in conjunction with-the colorectal surgeons and the patient, with 49% recommending subtotal colectomy given the risk of metachronous CRC. Recommendations for gastric cancer screening with esophagogastroduodenoscopy (EGD) varied by region, with screening EGD supported by only 56% of providers. Routine small-bowel screening with small-bowel capsule endoscopy rarely was recommended (7%). Most providers (78%) provided recommendations or made referrals for gynecologic cancer screening, although only 46% made recommendations for urologic screening. For other types of cancers, only 6% of providers recommended screening or surveillance for neurologic cancer, 15% for pancreatic/hepatobiliary cancer, and 27% for breast cancer, whereas the majority (60%) did not recommend screening/surveillance for any of these additional cancers (Table 3) .
Overall, only 35% of all respondents recommended aspirin chemoprophylaxis at this time, and several noted in their comments a recommended starting age between 20 and 30 years old, although the stopping age was unclear (Table 3) . Reported doses prescribed varied from 100 to 650 mg/d, and many respondents advocated that dosing recommendations await the results of the ongoing Cancer Prevention Project (CAPP)3 trial. Proton pump inhibitor co-therapy to decrease risk of toxicity was rarely recommended (Table 3) .
Future Issues
Many respondents agreed that over the next 5 to 10 years, the field of familial cancer syndromes will bring changes to Lynch syndrome case finding and assessment, with 78% agreeing that routine risk assessment in the general population is at least somewhat likely (Supplementary Table 4 ).
Discussion
Our study was designed to evaluate worldwide clinical practice patterns related to Lynch syndrome diagnosis and management. Although institutions around the world dedicated to the care of persons with Lynch syndrome seem to agree on the importance of case finding, mutation identification, information dissemination, and cancer risk management, the approach taken varies by region and institution.
Wide variability was reported in the use of routine tumor testing as a case-finding strategy for Lynch syndrome. Many experts endorse reflex colorectal tumor testing as a strategy to identify persons with Lynch syndrome, given the ability to identify an additional 12% to 28% of cases of Lynch syndrome vs use of clinical criteria alone. [17] [18] [19] [20] In addition, reflex tumor testing of endometrial cancers has been found to identify Lynch syndrome mutation carriers in 1.8% to 3.9% of patients. 21, 22 Establishing partnerships with surgical pathology colleagues and standardized protocols can help make reflex tumor testing a more widely accepted practice. 23 Wider availability and use of risk assessment tools also might help providers identify at-risk families that may benefit from referral to a genetics clinic. 24 In cases in which IHC is suggestive of-but germline testing does not identify-a Lynch syndrome mutation, testing for biallelic somatic mutations can be performed, but most providers comment that it still is too costly with minimal benefit and limited availability. Of those who did use this type of testing, some reported cases in which biallelic (sporadic) mutations were identified, relieving patients from unnecessary Lynch syndrome surveillance. Multigene panel use was reported by some but not all participants. This is a rapidly evolving area of practice, in which we anticipate rapid changes in technology, its availability, and its costs. Most experts currently believe that, given the complexities involved, genetic testing should be performed in conjunction with genetic counseling by trained professionals owing to the potential clinical, psychosocial, financial, and ethical concerns. 25 It has been estimated that the cascade effect of identifying a Lynch syndrome proband on average leads to an additional 3 relatives identified with Lynch syndrome. 26 We found that the majority of respondents estimated an overall uptake of genetic testing in at-risk family members to be less than 50%, consistent with previous studies. In a systematic review by Sharaf et al, 27 52% or fewer at-risk first-degree relatives of patients with Lynch syndrome received genetic testing, and multiple factors were associated with increased uptake, including demographics (age <50 y, female sex, parenthood, level of education, employment, and participation in medical studies), lack of depressive symptoms, and possibly family history. Other studies have noted the failure of probands to communicate the diagnosis and recommendations for testing to the first-degree relatives as a barrier to genetic testing by relatives. 28 Given that primarily passive information dissemination processes to relatives currently dominate, tools to help probands tailor communication with their at-risk family members might be valuable. For example, researchers have created websites (such as www.Kintalk. org) that allow relatives to securely share their genetic testing results, as well as media content that provides objective and standardized information. 29, 30 The question of active dissemination to at-risk family members with or without the need of proband approval is a delicate ethical and public health issue balancing patient privacy and duty to warn. 31, 32 Once patients have been diagnosed with Lynch syndrome, the prospect of a lifetime of screening, surveillance, and other risk-reduction interventions can be daunting for some. In survey studies, the most important characteristics that predicted colonoscopy screening compliance in Lynch syndrome families were mutationpositive status (in those tested) and meeting with a genetic counselor. [33] [34] [35] These data support the importance of determining mutation carrier status to identify those likely to benefit from intensive surveillance, as well as to ensure judicious use of resources.
Respondents endorsed the importance of colonoscopic surveillance in Lynch syndrome with intervals of 1 to 2 years. Prospective studies have found that a colonoscopic screening interval of 1 to 2 years resulted in a lower CRC cumulative risk of 6% over the course of 10 years, compared with less-frequent surveillance intervals. 7 ,36,37 Cost-effectiveness analyses have found that screening for Lynch syndrome can be cost effective, despite substantial costs for case finding and intensive surveillance, provided that enough at-risk relatives participate in risk-reduction interventions.
38,39
Aspirin also has been recognized to play a role in CRC prevention. 40 The Colorectal Adenoma/Carcinoma Prevention Programme (now known as the Cancer Prevention Programme) 2 (CAPP2) trial assessed the effect of aspirin 600 mg/d on a primary end point of cancer incidence in carriers of Lynch syndrome mutations. 41 The study found a hazard ratio of 0.41 and an incidence rate ratio of 0.38 in per-protocol analysis of those who had completed 2 years of aspirin intervention. Despite these results, only a minority of respondents in our study (35%) recommend aspirin regularly for chemoprophylaxis at this time, probably because of the relatively high aspirin dose studied in CAPP2. CAPP3, started in 2013, aims to establish the optimum dose and duration of aspirin treatment. 42 Gastric cancer screening recommendations were less uniform, with screening being most common in Asia, North America, and South/Central America, which may reflect higher gastric cancer rates in the general population in Asia and South/Central America (with proposed etiologies including Helicobacter pylori and food preservation techniques).
Many respondents agreed that over the next 5 to 10 years, the field of familial cancer syndromes will evolve, raising challenges and opportunities beyond case finding and management in Lynch syndrome. The majority agreed that routine risk assessment in the general population is at least somewhat likely, especially with the development of online tools based on risk prediction models that can be used by patients and general practitioners directly. Opinions on the role of routine germline study in the general population were mixed. Respondents commented that genetic testing rapidly is becoming faster and cheaper, with several private companies creating full genome and panel-based tests that have become more accessible to patients. They also cautioned, however, that patients still will benefit from the time and expertise of specialized providers to guide and interpret the use of these tests.
The limitations of our study include that the IMRC represents institutions with the interest, expertise, and infrastructure to care for persons with Lynch syndrome, and members' answers probably are not generalizable beyond centers with special interest in Lynch syndrome. It is not known what fraction of all Lynch syndrome patients are managed by these institutions. There was a risk of response bias, with 63 responses of 128 clinical institutions represented. Any potential gaps and weaknesses in the current systems of care for this population are likely to be magnified in general practice. The variable response rate across regions limits the ability to make regional comparisons. A key issue is that 55% of respondents provided estimates, and not rigorous ascertainment of results. Finally, actual practice patterns may differ from what was reported. Future and current efforts by the IMRC to address these issues include plans for a combined repository of pedigree and lifestyle data, and for focus groups to help identify country-specific barriers to compliance with screening guidelines. Our survey could be administered during meetings of other interested professional groups, with efforts to increase response rates.
Our study suggests that there is widespread heterogeneity in management practices for Lynch syndrome worldwide. This likely reflects the rapid pace of emerging technology, regional differences in resources, and lack of definitive data for many clinical questions. In just a few decades, there has been a surge of advances in the knowledge and tools used for the diagnosis and management of Lynch syndrome patients and families, and breakthroughs in the understanding and management of genetic cancer predisposition syndromes are accumulating quickly. To better address and care for the large numbers of high-risk families, a concerted effort by clinicians, researchers, policy makers, and patient advocates will be required. This includes establishing the supporting infrastructure and allocating the resources necessary to deliver state-of-the-art management to all persons with Lynch syndrome or other genetic cancer syndromes. 
Supplementary Material
Supplementary Methods
Study Design and Target Population
The IMRC includes 143 institutions in 29 different countries (Supplementary Table 1 ).
Questionnaire Development and Dissemination
Multiple specific items under each theme were drafted by the authors. Specific items were written and refined in an iterative process. The questionnaire was pilot-tested by faculty members and genetic counselors in the Stanford Cancer Genetics Clinic and IMRC collaborators in Australia. The final questionnaire reflected the input provided during pilot testing (Supplementary Appendix).
Responses to questions were solicited in Likert-scale or yes/no formats, with space allowed for free-text comments. The questionnaire was made available from August 2015 to January 2016. Reminder e-mails were sent at the 2-month and 3-month marks to encourage additional participation. Responses were kept de-identified by institution and respondent. Demographic information including geographic location, setting, and number of annual referrals were collected for analysis purposes.
Data Management and Statistical Analysis
REDCap, a secure web application for building and managing online surveys and databases, was used for dissemination of the questionnaire and collection of responses. (Supplementary Table 1 and Supplementary Appendix) .
Supplementary Results
Sample Size
We had respondents who represented affiliated institutions, such as the German HELIOS Consortium, in which provider teams overlapped, and as such practice patterns were the same for these institutions. We therefore counted these consortiums as one entity to minimize redundancy.
Responding Institutions and Services Provided
Genetic counseling services provided at the majority of the institutions included family history evaluation, ordering of tumor testing, genetic testing, risk assessment, and management recommendations, with 73% of respondents also providing screening/surveillance services (Table 1) .
Referrals and Case-Finding Practices
Nearly half of new patient referrals originated from specialty care (47%), followed by primary care (21%), cascade testing in relatives of mutations carriers, casefinding programs, and self/direct referrals ( Table 2) .
There was a notable difference in case-finding programs by region, with 84% of North American centers reporting use of a program involving widespread reflex tumor testing (Table 2) .
Work-Up and Genetic Testing
The most common criteria used to quantitate the pretest yield of genetic testing included Amsterdam II criteria, Bethesda Guidelines, and the PREdiction Model for gene Mutations 1,2,6 model (Supplementary Table 2 ). [1] [2] [3] [4] [5] [6] For patients without cancer, 69% of respondents made efforts all or most of the time to obtain tumor tissue from affected relatives, and 82% made efforts all or most of the time to bring in relatives with a history of Lynch syndrome-associated cancer (Supplementary Table 2 ).
Dissemination of Information to At-Risk Family Members and Cascade Testing
The majority of respondents used passive means to disseminate information to at-risk family members (Supplementary Table 3 ). The most common methods used for information dissemination to at-risk family members were education and expectation of word-ofmouth dissemination by the patient, and letters given to patients to disseminate to their family members, although the use of reflex family letters sent with the patient's knowledge was reported by <20% of respondents (Supplementary Table 3 ). Although respondents from most regions reported that local laws did not allow for active dissemination of genetic diagnoses information without the knowledge of the patient, a few providers in Australasia and Europe commented that laws existed allowing this practice in their regions (Supplementary Table 3) .
Only 1 respondent from Asia and 3 respondents from Europe estimated genetic testing uptake rates of up to 75% to 99% in relatives (Figure 3 ).
Management Practices
In Australasia, 83% of providers recommended an annual colonoscopy, compared with only 12% in Europe, where 59% of providers recommended colonoscopy every 2 years.
Respondents commented that decisions for more limited surgical interventions such as segmental resections took into consideration factors such as age, comorbidities, and compliance with colonoscopic surveillance. Some respondents also commented that many patients already had undergone more limited surgeries for CRC before receiving their Lynch syndrome diagnosis (Table 3) .
Although providers in Asia (75%), North America (84%), and South/Central America (100%) generally advised at least a 1-time esophagogastroduodenoscopy for gastric cancer screening, those in Australasia (83%) and Europe (82%) did not routinely support it (Table 3) . The comments from North American respondents indicated that although it is of low yield, it often still is performed periodically in conjunction with surveillance colonoscopy, especially in those with a family history of gastric or duodenal cancer or those of Asian descent. Respondents commented that the rationale for not recommending routine small-bowel screening included low overall risk of small-bowel malignancies, except in cases of patients with a significant family history.
Most providers (78%) gave recommendations or made referrals for gynecologic cancer screening ( Table 3 ). The modalities used included transvaginal ultrasound (86%), pelvic examination (77%), endometrial biopsy (70%), and cancer antigen 125 measurement (56%). Among providers who recommended screening or surveillance for urinary tract cancer, modalities of choice included urinalysis (84%), cytology (60%), and renal ultrasound (28%) ( Table 3) . Regarding gynecologic and urinary tract cancers, providers agreed on the need to discuss that screening has not been shown to reduce morbidity or morality from these cancers. There was considerable variation by region regarding recommendations for prophylactic hysterectomy and oophorectomy, with some providers commenting that surgical considerations depended on family history, childbearing, and plans for colectomy.
Rates of aspirin chemoprophylaxis recommendation ranged from 20% to 50% by region (Table 3) . Some respondents recommended that aspirin initiation be discussed in conjunction with general practitioners, along with consideration of the patient's cardiovascular risk.
Future Issues
The majority (78%) agreed that routine risk assessment in the general population is at least somewhat likely, with comments noting the development of online tools based on risk prediction models that can be used by patients and general practitioners directly (Supplementary Table 4 ). Opinions on the role of routine germline study in the general population were more varied, with only 58% of respondents finding it at least somewhat likely that this will occur, whereas 91% believe it is at least somewhat likely that direct germline testing will replace tumor testing in the screening or evaluation for possible Lynch syndrome (Supplementary Table 4 ).
Additional Analysis
Distribution of respondent institutions by referral volume. To evaluate whether the variability noted could be related to differences in institution or consortia volume, rather than just regional differences, we conducted additional analyses to evaluate differences in genetic testing and management by volume. Based on the distribution of the reported number of annual referrals for suspected Lynch syndrome, the institutions were divided into tertiles of low (<100 referrals/y), medium (101-250 referrals/y), or high (>250 referrals/y) volume. Statistical analysis was performed (2-sided Fisher exact test).
Profile of respondent institutions by referral volume. A regional difference was noted in institution referral volume (P ¼ .0039), with no high-volume institutions found in Asia or Australasia (Supplementary Table 5 ). There was no statistical significance in institution volume based on practice setting.
Work-up and genetic testing practices by referral volume. Although institutions with a higher referral volume did show larger numbers of annual new cases diagnosed (P ¼ .0023), overall there was no statistical significance noted in work-up and genetic testing practices by institution referral volume (Supplementary Table 6 ). Table 7) , we only found a statistically significant difference in recommendations for gynecologic screening/surveillance, in which 91% of low-volume and 88% of high-volume institutions recommended screening/surveillance, whereas only 56% of mediumvolume institutions did so. No system in place for dissemination 1 (12. 
